DR info

臨床試験数 : 4 / 薬物数 : 7 - (DrugBank : 3) / 標的遺伝子数 : 1 - 標的パスウェイ数 : 51

薬物ごとの開発者（Primary Sponsor）、臨床試験情報（抜粋）です。

Prodarsan
   DNage B.V.
      2010   Phase 1/Phase 2   NCT01142154   United States;
Quercetin
   The First Medical Center of PLA General Hospital
      2019   Phase 0   ChiCTR1900026719   China;
Sirolimus
   Premier Specialists, Australia
      2016   Phase 2   NCT03016715   Australia;
Sirolimus,
   Stanford University
      2016   Phase 2   NCT02960997   United States;
Vehicle
   Premier Specialists, Australia
      2016   Phase 2   NCT03016715   Australia;
   Stanford University
      2016   Phase 2   NCT02960997   United States;
Vitamin C
   The First Medical Center of PLA General Hospital
      2019   Phase 0   ChiCTR1900026719   China;